Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Research Article

Comparison of Metformin-sulfonylurea and Metformin-acarbose Combination Therapies on Glycemic Outcomes: A Retrospective Cohort Study

Author(s): Wafa Wafa, Renni Septini and Rani Sauriasari*

Volume 18, Issue 7, 2022

Published on: 12 January, 2022

Article ID: e031121197656 Pages: 7

DOI: 10.2174/1573399818666211103161917

Price: $65

Abstract

Objective: Pharmacological therapy for type 2 diabetes mellitus features various combinations of treatments, with different therapies providing different levels of effectiveness. In clinical settings, choices are driven by cost, effectiveness, and safety considerations, and these choices are still under question in Indonesia. This study aimed to compare the effectiveness of metformin-sulfonylurea and metformin-acarbose combination therapies on glycemic parameters in patients with type 2 diabetes mellitus.

Methods: This study was carried out at Gatot Soebroto Army Hospital in Jakarta and utilized a retrospective cohort study design. Participants had consumed the same drug without switching for six months and were divided into a metformin-sulfonylurea group (n = 100) and a metformin-acarbose group (n = 100). The effectiveness of treatment was evaluated by considering hemoglobin A1c (HbA1c), two hours postprandial glucose, and fasting blood glucose.

Results: After six months’ consumption, there were no statistical differences between results for the metformin-sulfonylurea and metformin-acarbose groups in terms of change of HbA1c (p = 0.062), controlled two hours postprandial blood glucose (p = 0.649), and controlled fasting blood glucose (p = 0.282). Regular exercise was the most significant factor for constant/decreased HbA1c, whereas being male and following a diet were the most significant factors for controlled two hours postprandial blood glucose and fasting blood glucose, respectively.

Conclusion: Based on the analysis performed, there was no significant difference in the effectiveness of six months’ consumption of metformin-sulfonylurea and metformin-acarbose on HbA1c, two hours postprandial blood glucose, and fasting blood glucose.

Keywords: Metformin, sulfonylurea, acarbose, type 2 diabetes mellitus, HbA1c, two hours postprandial blood glucose, fasting blood glucose.

[1]
International Diabetes Federation. IDF clinical practice recommendations for managing type 2 diabetes in primary care. International Diabetes Federation 2017.
[2]
Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A. Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2015 Pengurus Besar Perkumpulan Endokrinologi Indonesia. Jakarta, Indonesia: PB PERKENI 2015.
[3]
International Diabetes Federation. IDF Diabetes Atlas. (7th ed). International Diabetes Federation 2015.
[4]
Gao X, Cai X, Yang W, Chen Y, Han X, Ji L. Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations. J Diabetes Investig 2018; 9(2): 321-31.
[http://dx.doi.org/10.1111/jdi.12711] [PMID: 28685995]
[5]
Nindyatami C. Analisis efektivitas-biaya terapi kombinasi metformin-akarbose dan metformin-sulfonilurea pada pasien diabetes mellitus tipe 2 di RSPAD gatot soebroto 2018.
[6]
Kupsal K, Mudigonda S, Nyayapathi VBKS, Neelala K, Hanumanth SR. Metformin combinatorial therapy for type 2 diabetes mellitus. J Metab Syndr 2016; 5: 210.
[http://dx.doi.org/10.4172/2167-0943.1000210]
[7]
Saboo B, Reddy GC, Juneja S, Kedia AK, Manjrekar P, Rathod R. Effectiveness and safety of fixed dose combination of acarbose/metformin in Indian type 2 diabetes patients: Results from observational GLOBE Study. Indian J Endocrinol Metab 2015; 19(1): 129-35.
[http://dx.doi.org/10.4103/2230-8210.146868] [PMID: 25593840]
[8]
Situasi dan analisis diabetes di Indonesia Jakarta (Indonesia): pusat data dan informasi kementerian republik kesehatan Indonesia 2014; Jakarta. Indonesia: Indonesian ministry of health 2014.
[9]
Mihardja L, Soetrisno U, Soegondo S. Prevalence and clinical profile of diabetes mellitus in productive aged urban Indonesians. J Diabetes Investig 2014; 5(5): 507-12.
[http://dx.doi.org/10.1111/jdi.12177] [PMID: 25411617]
[10]
Sakurai M, Nakamura K, Miura K, et al. Family history of diabetes, lifestyle factors, and the 7-year incident risk of type 2 diabetes mellitus in middle-aged Japanese men and women. J Diabetes Investig 2013; 4(3): 261-8.
[http://dx.doi.org/10.1111/jdi.12033] [PMID: 24843664]
[11]
Rosak C, Mertes G. Critical evaluation of the role of acarbose in the treatment of diabetes: Patient considerations. Diabetes Metab Syndr Obes 2012; 5: 357-67.
[http://dx.doi.org/10.2147/DMSO.S28340] [PMID: 23093911]
[12]
Weng J, Soegondo S, Schnell O, et al. Efficacy of acarbose in different geographical regions of the world: Analysis of a real-life database. Diabetes Metab Res Rev 2015; 31(2): 155-67.
[http://dx.doi.org/10.1002/dmrr.2576] [PMID: 25044702]
[13]
Hara T, Nakamura J, Koh N, Sakakibara F, Takeuchi N, Hotta N. An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Diabetes Care 1996; 19(6): 642-7.
[http://dx.doi.org/10.2337/diacare.19.6.642] [PMID: 8725865]
[14]
Raman PG. Management of postprandial blood glucose in diabetes mellitus. Arch Dia Obes 2018; 1(5): 98-101.
[15]
Fahmiyah I, Latra I N. Faktor yang memengaruhi kadar gula darah puasa pasien diabetes melitus tipe 2 di poli diabetes RSUD Dr. J Sains dan Seni 2016; 5(2): 456-61.
[16]
Fazil QAA. Investigation on the relationship between cholesterol and blood glucose levels using decision tree method in healthy subjects. IEEE 2nd I2CACIS 2017.
[http://dx.doi.org/10.1109/I2CACIS.2017.8239051]
[17]
Widodo C, Tamtomo D, Prabandari AN. Hubungan aktivitas fisik, kepatuhan mengkonsumsi obat anti diabetik dengan kadar gula darah pasien diabetes mellitus di fasyankes primer Klaten. J Sist Kesehat 2016; 2(36): 63-9.
[18]
Nasri H. Rafieian-kopaei. metformin: Current knowledge. Journal of research in medical science. Official J Isfahan Univ of Med Sci 2014; 19(7): 658-64.
[19]
Sola D, Rossi L, Schianca GPC, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci 2015; 11(4): 840-8.
[http://dx.doi.org/10.5114/aoms.2015.53304] [PMID: 26322096]
[20]
Tschöpe D, Bramlage P, Binz C, et al. Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients-an analysis of the DiaRegis registry. Cardiovasc Diabetol 2011; 10(1): 66.
[http://dx.doi.org/10.1186/1475-2840-10-66] [PMID: 21756359]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy